| ID | 1139 |
| Name of the vaccine | Prevnar 20 |
| Microbe | Bacteria |
| Disease name | Pneumococcal |
| Name of bacteria | Streptococcus pneumoniae |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 18 years and older |
| Description of the vaccine | Pneumococcal 20-valent conjugate vaccine. |
| Name of the manufacturer | Pfizer |
| Name of the manufacturing country | Philadelphia |
| Year of manufacture | 2021 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive, facultative anaerobic bacteria. |
| Efficacy | Assessed by measuring serotype-specific serum OPA of antibodies at 1-month post vaccination. |
| Vaccine formulation | Suspension for injection |
| Dosage | Single dose (0.5 ml). |
| Mechanism of action | Opsonophagocytic killing of S. pneumoniae. |
| Route of administration | Intramuscular |
| Indications | Prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. |
| Export | NA |
| Approval | US FDA |
| Adjuvant | Aluminium phosphate |
| Repurposing | NA |
| Side effects of vaccine | Injection site pain and swelling, muscle pain, fatigue , headache and arthralgia. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/149987/download |
| Other name | NA |
| Additional Links | NA
|